Meeting
2023 ASCO Annual Meeting
OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.
Authors
Russell J. Schilder
Thomas Jefferson University Hospital, Philadelphia, PA
Russell J. Schilder , Mark S. Shahin , Mitchell Edelson , Norman G. Rosenblum , Ashley Douglas , Saveri Bhattacharya , Tarek Sahmoud , Elizabeth Burton , Avnish K Bhatia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT04719273
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5601)
DOI
10.1200/JCO.2023.41.16_suppl.5601
Abstract #
5601
Poster Bd #
296
Abstract Disclosures
Similar Posters
First Author: B.J. Rimel
Poster
2023 ASCO Annual Meeting
A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.
First Author: Guangwen Yuan
Poster
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Dawei Chen
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang